Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality

Farah Olleik, Mohammed Hussein Kamareddine, Jenna Spears, Gary Tse, Tong Liu, Gan Xin Yan

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Mexiletine, a class Ib antiarrhythmic drug, exhibits its major antiarrhythmic effect via inhibition of the fast and late Na+ currents in myocardial tissues that are dependent on the opening of Na+ channels for their excitation. Through a comprehensive examination of mexiletine's therapeutic benefits and potential risks, we aim to provide valuable insights that reinforce its role as a vital therapeutic option for patients with ventricular arrhythmias, long QT syndrome, and other heart rhythm disorders. This review will highlight the current understandings of the antiarrhythmic effects and rationales for recent off-label use and address the mortality and proarrhythmic effects of mexiletine utilizing published basic and clinical studies over the past five decades.

Original languageEnglish
Pages (from-to)1348-1356
Number of pages9
JournalPACE - Pacing and Clinical Electrophysiology
Volume46
Issue number11
DOIs
Publication statusPublished - Nov 2023

Keywords

  • antiarrhythmic effects
  • atrial fibrillation
  • drug safety
  • long QT syndrome
  • mexiletine
  • mortality
  • pharmacokinetics
  • proarrhythmias
  • ventricular tachycardia

Fingerprint

Dive into the research topics of 'Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality'. Together they form a unique fingerprint.

Cite this